GTCR Announces Sale of Actient to Auxilium Pharmaceuticals
Chicago, IL — April 29, 2013
GTCR, a leading private equity firm, announced today it has sold its portfolio company, Actient Holdings LLC (“Actient”), to Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL, “Auxilium”), a specialty biopharmaceutical company. Headquartered in Lake Forest, Illinois, Actient is a specialty pharmaceutical company focused on developing, acquiring and marketing products that significantly improve patient outcomes.
Actient was formed in March 2009 in partnership with GTCR. Through a series of five acquisitions, Actient built a diversified portfolio of commercial products and pipeline programs to create a unique specialty pharmaceutical company focused on the treatment of urological indications.
“Our partnership with Actient CEO Ed Fiorentino exemplifies GTCR’s Leaders Strategy™,” said GTCR Managing Director Dean Mihas. “We created Actient with a strategy to build a leading specialty pharmaceutical company through the acquisition of companies and products. Through a series of transactions, Ed and the team have built a growing urology specialty company. The strategic acquisition of Actient is the culmination of this successful partnership and GTCR’s healthcare strategy.” Ben Daverman, GTCR Vice President, added, “Actient has been an excellent partnership for GTCR, and we are truly appreciative of the many fine efforts by Ed and his management team.”
“I’d like to thank GTCR for their efforts in helping Actient become a significant specialty company.” said Mr. Fiorentino. “We have had a great partnership with GTCR and we look forward to working with Auxilium to continue Actient’s efforts to develop products that significantly improve patient outcomes.”
Jefferies LLC served as Actient’s financial advisor and Kirkland & Ellis LLP provided legal counsel.
Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare and Information Services & Technology industries. The Chicago-based firm pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $10 billion in over 200 companies. For more information, please visit www.gtcr.com.
About Actient Pharmaceuticals LLC
Actient is a specialty products company focused on therapeutics to improve patient outcomes. The company was formed to acquire companies and products with a focus on select physician specialties. For more information, please visit www.actientpharma.com.